RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All Migraine Articles

Amgen, Novartis, Alder, Allergan, BioHaven, Lilly, and Teva are all anticipating FDA approval of their novel anti-CGRP chronic migraine preventive medications in 2018
CGRP receptor antagonists have been well tolerated in studies.
Findings challenge a 2006 FDA advisory, questioning its validity
Lilly survey results point to need for new headache and migraine treatments as well as patient education.
While migraines are an acute pain issue for many, promising results for ubrogepant are encouraging.
Device from Cefaly Technology promises to abort migraines more effectively than triptans.
A patient’s perception of stress appears to offer a good forecast factor to predict the onset of episodic migraines.
Two studies published in the New England Journal of Medicine report favorable results when targeting calcitonin gene-related peptide with mAb treatments for migraine pain.
A new study demonstrated that dermal application of zolmitriptan may provide significant relief from headache pain and most bothersome migraine symptoms.
For patients with migraines, defining the migraine will ensure proper selection of the medications and complementary therapies based on individual needs to address comorbidities and patient preferences.
Headache expert Duren Michael Ready, MD, provides tips on what to try when nothing else is working.
Case presentation of a chronic migraine patient in her mid-20's. Learn step-by-step treatment plan.
Up to 4% of adults suffer from chronic headaches, mostly migraines. Dr. Lawrence Robbins reviews what we know about migraine types, comorbidities, as well as migraine triggers, and treatments.
Patients with refractory chronic migraine (RCM) experience a great deal of disability related to their chronic headaches.
SHOW MAIN MENU
SHOW SUB MENU